News

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD ...